A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event ACCLAIM-Lp(a)

Brief description of study

This study is being done to learn more about the safety and effectiveness of the drug Lepodisiran (LY3819469) in lowering Lp(a) levels and reducing cardiovascular events in people with cardiovascular disease or who are at risk for a first cardiovascular (CV) event and provide additional evidence for the potential clinical benefits of Lepodisiran. Lp(a) is a molecule in the blood that carries cholesterol, and is a known risk factor for cardiovascular disease (CVD). High levels of Lp(a) increase the risk of cardiovascular events such as heart attacks, stroke and aortic stenosis. Unlike other risk factors, for example blood cholesterol levels, which can be influenced by diet, exercise, or obesity, Lp(a) levels are inherited and stay relatively stable from childhood. Until recently, the role of Lp(a) was not well understood and therefore it was not routinely tested for in patients.


Clinical Study Identifier: s24-00380
ClinicalTrials.gov Identifier: NCT06292013
Principal Investigator: Howard Weintraub.
Other Investigators: Arthur Z Schwartzbard, Michael Seth Garshick.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.